

§Appl. No. 10/067,482  
Amdt. dated January 14, 2005  
Reply to Office Action of, October 21, 2004

**Listing of Claims:**

Please **amend** the claims as follows:

**Claim 1 (Withdrawn)** An isolated polynucleotide comprising a polynucleotide sequence which codes without interruption for human ANH401 having the amino acid sequence set forth in SEQ ID NO 2, or a complement thereto.

**Claim 2 (Withdrawn)** An isolated human polynucleotide of claim 1, wherein the polynucleotide sequence which codes for human ANH401 has the nucleotide sequence set forth in SEQ ID NO 1.

**Claim 3 (Withdrawn)** An isolated human ANH401 polynucleotide comprising, polynucleotide sequence having 99% or more sequence identity along its entire length to the polynucleotide sequence set forth in SEQ ID NO 1, which codes without interruption for ANH401, or a complement thereto, and which has NADP binding activity.

**Claim 4 (Withdrawn)** An isolated human ANH401 polynucleotide of claim 3 which has dehydrogenase activity.

**Claim 5 (Withdrawn)** An isolated polynucleotide which is specific for an ANH401 of claim 1 and which codes for a polypeptide comprising amino acids 271-308 of SEQ ID NO 2.

**Claim 6 (Currently Amended)** An isolated human ANH401 polypeptide comprising, the amino acid sequence set forth in SEQ ID NO 2.

§Appl. No. 10/067,482  
Amdt. dated January 14, 2005  
Reply to Office Action of, October 21, 2004

**Claim 7 (Original)** An isolated polypeptide which is specific for an ANH401 of claim 6 and which codes for a polypeptide comprising amino acids 271-308 of SEQ ID NO 2.

**Claim 8 (Currently Amended)** An isolated human ANH401 polypeptide comprising an amino acid sequence having 99% or more sequence identity along its entire length to the amino acid sequence set forth in SEQ ID NO 2 and which hybridizes to the complement of SEQ ID NO:1 under high stringency conditions comprising incubating overnight at 65°C with 6X SSC, 0.5% SDS, 100µg/ml denatured salmon sperm DNA, 5X Denhardt's solution, and 50% formamide, followed by washing with 0.1% SSC and 0.1% SDS for 30 min at 65°C, and which comprises the sequence CDLFIQ from amino acid 303-308 of SEQ ID NO:2 (SEQ ID NO:2).

**Claim 9 (Original)** An isolated human ANH401 polypeptide of claim 8 which has dehydrogenase activity.

**Claim 10 (Withdrawn)** A method of treating a vascular disease or a disease association with vascularization, comprising:

administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of said ANH401 of claim 1.

**Claim 11 (Withdrawn)** A method of claim 10, wherein said agent is an antibody specific for ANH401.

**Claim 12 (Withdrawn)** A method of claim 11, wherein said antibody is specific for an epitope of amino acids 303-308 of SEQ ID NO 2.

§Appl. No. 10/067,482  
Amdt. dated January 14, 2005  
Reply to Office Action of, October 21, 2004

**Claim 13 (Withdrawn)** A method for identifying an agent that modulates the expression of ANH401 in cells capable of forming blood vessels, comprising:

contacting said cells with a test agent under conditions effective for said test agent to modulate the expression of ANH401 of claim 1 in said cells, and  
determining whether said test agent modulates said ANH401.

**Claim 14 (Withdrawn)** A method of claim 13, wherein said agent is an antibody specific for ANH401.

**Claim 15 (Withdrawn)** A method of determining the angiogenic index of a sample comprising cells, comprising:

assessing, in said sample, the expression level of ANH401 of claim 1, whereby said levels are indicative of the angiogenic index.

**Claim 16 (Withdrawn)** A method of claim 15, wherein the angiogenic index is assessed by polymerase chain reaction using polynucleotide primers specific for said genes.

**Claim 17 (Withdrawn)** A method of claim 15, wherein the angiogenic index is assessed by detecting polypeptides coded for by said genes using specific antibodies.

**Claim 18 (Withdrawn)** A method of regulating angiogenesis in a system comprising cells capable of forming blood vessels, comprising:

administering to said system an effective amount of a modulator of ANH401 polynucleotide of claim 1, or a polypeptide coded thereby, under conditions effective for the modulator to modulate said polypeptide, whereby angiogenesis is regulated.

§Appl. No. 10/067,482  
Amdt. dated January 14, 2005  
Reply to Office Action of, October 21, 2004

**Claim 19 (Withdrawn)** A method of claim 18, wherein the modulator is an antibody specific-for said polypeptide.

**Claim 20 (Withdrawn)** A method of claim 18, wherein the antibody is conjugated to a cytotoxic or cytostatic agent.

**Claim 21 (Withdrawn)** A method of claim 18, wherein regulating angiogenesis is inhibiting angiogenesis;

**Claim 22 (Withdrawn)** A method of claim 18, wherein regulating angiogenesis is stimulating angiogenesis;

**Claim 23 (Withdrawn)** A method of claim 18, wherein the system is an *in vitro* cell culture or *in vivo*.

**Claim 24 (Withdrawn)** A method of claim 18, wherein the system is a patient having a cancer, coronary artery disease, myocardial ischemia, or coronary arteriosclerosis.

**Claim 25 (Withdrawn)** A non-human, transgenic mammal whose genome comprises a functional disruption of ANH401 of claim 1.

**Claim 26 (Withdrawn)** A method of advertising ANH401 of claim 1 for sale, commercial use, or licensing, comprising,

displaying in a computer-readable medium a polynucleotide set forth in SEQ ID NO 1, complements thereto, or a polypeptide set forth in SEQ ID NO 2.

§Appl. No. 10/067,482  
Amdt. dated January 14, 2005  
Reply to Office Action of, October 21, 2004

**Claim 27 (Withdrawn)** An antibody which is specific for an epitope coding for amino acids 303-308 of a human ANH401 of claim 8 and which is specific for said ANH401.